Tang, J.-L., W.-Z. Wang, J.-G. An, Y.-H. Hu, S.-H. Cheng, and S. Griffiths. 2009. How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: A survey in a Chinese city. International Journal of Epidemiology 39(1):244-254.

Thavorn, K., and N. Chaiyakunapruk. 2008. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tobacco Control 17(3): 177-182.

Weinstein, M. C., B. O’Brien, J. Hornberger, J. Jackson, M. Johannesson, C. McCabe, and B. R. Luce. 2003. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices modeling studies. Value in Health 6(1):9-17.

Wessels, F. 2007. Eprosartan in secondary prevention of stroke: The economic evidence. Cardiovascular Journal of Africa 18(2):95-96.

Whelton, P. K., J. He, and P. Muntner. 2004. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. Journal of Human Hypertension 18(8):545-551.

WHO (World Health Organization). 2006. WHO country health information. http://www.who.int/nha/country/en/ (accessed February 5, 2010).

WHO. 2010. Choosing Interventions that are Cost-Effective (WHO-CHOICE). http://www.who.int/choice/en/ (accessed March 15, 2010).

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement